专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005014623A2 COMPOUNDS COMPRISING LPA 审中-公开
标题翻译：包含LPA的化合物
公开(公告)号：WO2005014623A2
公开(公告)日：2005-02-17
申请号：PCT/DK2004000527
申请日：2004-08-06
申请人： ENKAM PHARMACEUTICALS AS , ALBRECHTSEN MORTEN , BOCK ELISABETH , BEREZIN VLADIMIR , HOLM ARNE
发明人： ALBRECHTSEN MORTEN , BOCK ELISABETH , BEREZIN VLADIMIR , HOLM ARNE
IPC分类号： C07K14/705 , C07K14/71 , C07K14/78 , C07K19/00 , C07K7/00
CPC分类号： C07K14/71 , C07K14/70503 , C07K14/78 , C07K19/00
摘要： The present invention relates to new peptide compounds capable of binding to fibroblast growth factor receptor (FGFR), said compounds comprising two individual amino acid sequences, wherein at least one of the two amino acid sequences is capable of binding to FGFR. The invention discloses the amino acid sequences of the compounds and features pharmaceutical compositions comprising thereof. Invention also relates to uses of the compounds and pharmaceutical compositions comprising thereof for the treatment or prevention of different pathological conditions, wherein FGFR plays a role in pathology and/or recovery from the disease. New peptide compounds of the invention are obtainable by the ligand presenting assembly (LPA) method.
摘要翻译：本发明涉及能够结合成纤维细胞生长因子受体（FGFR）的新肽化合物，所述化合物包含两个单独的氨基酸序列，其中两个氨基酸序列中的至少一个能够结合FGFR。本发明公开了所述化合物的氨基酸序列并且特征在于包含其的药物组合物。本发明还涉及所述化合物和包含其的药物组合物用于治疗或预防不同病理学病症的用途，其中FGFR在疾病的病理学和/或恢复中起作用。本发明的新肽化合物可通过配体呈递组装（LPA）方法获得。

2. 发明申请

WO2004056865A3 METHOD OF MODULATION OF INTERACTION BETWEEN RECEPTOR AND LIGAND 审中-公开
标题翻译：受体和配体之间相互作用的调节方法
公开(公告)号：WO2004056865A3
公开(公告)日：2005-02-24
申请号：PCT/DK0300901
申请日：2003-12-18
申请人： ENKAM PHARMACEUTICALS AS , BEREZIN VLADIMIR , ALBRECHTSEN MORTEN , BOCK ELISABETH
发明人： BEREZIN VLADIMIR , ALBRECHTSEN MORTEN , BOCK ELISABETH
IPC分类号： A61K38/00 , C07K7/06 , C07K7/08 , C07K16/22 , G01N33/566 , G01N33/74 , C07K7/00
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C07K16/22 , G01N33/566 , G01N33/74 , G01N2333/50
摘要： The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound. The invention further describes an antibody capable of binding to the above binding site and/or to an epitope comprising an amino acid sequence essential for executing the receptor ligand interaction through said binding site. The invention also concerns a variety of uses of the disclosed methods, peptide sequences and antibodies. The invention in preferred embodiments concerns the binding site of the fibroblast growth factor receptor (FGFR) on FGFR ligands, compounds capable of modulating the receptor ligand interaction through said binding site, and antibody capable of recognition of said binding site.
摘要翻译：本发明涉及调节至少两种蛋白质之间的相互作用的方法，其中两种蛋白质中的至少一种是功能性细胞表面受体，而另一种蛋白质是受体配体。本发明的特征在于所述功能性细胞表面受体在受体配体上的结合位点，并公开了一系列氨基酸序列，其是所述结合位点结构的一部分和/或参与受体和配体之间的相互作用。此外，本发明的特征在于分子设计和筛选能够通过所述结合位点调节功能性细胞表面受体和受体配体之间的相互作用的候选化合物的方法，并提供了鉴定这种化合物的筛选试验。本发明还描述了能够结合上述结合位点和/或包含通过所述结合位点执行受体配体相互作用所必需的氨基酸序列的表位的抗体。本发明还涉及所公开的方法，肽序列和抗体的各种用途。本发明在优选实施方案中涉及成纤维细胞生长因子受体（FGFR）对FGFR配体的结合位点，能够通过所述结合位点调节受体配体相互作用的化合物和能够识别所述结合位点的抗体。

3. 发明申请

WO0183707A3 CHONDROCYTE CULTURES AND ANTI-ANGIOGENIC FRACTIONS THEREFROM 审中-公开
标题翻译： CHONDROCYTE文化和抗生素分类
公开(公告)号：WO0183707A3
公开(公告)日：2002-04-18
申请号：PCT/DK0100297
申请日：2001-05-01
申请人： MEDICO KEMISK LAB , OLSEN OLE , ALBRECHTSEN MORTEN , DALKIAER MIKKEL , LITTLE MARIE LOUISE OERBECH
发明人： OLSEN OLE , ALBRECHTSEN MORTEN , DALKIAER MIKKEL , LITTLE MARIE-LOUISE OERBECH
IPC分类号： A61K35/32 , A61K35/64 , A61K38/39 , C12N5/00 , C12N5/077 , C12P21/00 , C12N5/06
CPC分类号： C12N5/0655 , C12N2502/1317
摘要： The present invention concerns the development of anti-angiogenic, anti-inflammatoric, lysozomic and/or anti-collagenolytic agents and/or collagen and/or chondroitinsulphate from cultured chondrocytes. The chondrocytes are collected from a wide variety of animals, preferably elasmobranches cartilage and a detailed culturing procedure is described. The cartilage may be obtained from dead animals or as a biopsy from living animals. Then the chondrocytes are denuded from the extracellular matrix. Thereafter the chondrocytes are cultured to produce the agents, which are then isolated and purified.
摘要翻译：本发明涉及来自培养的软骨细胞的抗血管生成，抗炎，溶血和/或抗胶原蛋白和/或胶原和/或软骨素硫酸盐的发展。从多种动物收集软骨细胞，优选分离软骨，并描述详细的培养方法。软骨可以从死亡动物或活体动物的活组织检查获得。然后软骨细胞从细胞外基质中剥离。此后，将软骨细胞培养以产生试剂，然后分离和纯化。

4. 发明申请

WO2004006898A3 USE OF COMPOUNDS CAPABLE OF INHIBITING THE PROTEOLYTIC PROCESSING OF SEMAPHORINS FOR PREVENTION, TREATMENT, DIAGNOSIS AND PROGNOSIS OF AN INVASIVE DISEASE 审中-公开
标题翻译：使用可以抑制血清抑制作用进行预防，治疗，诊断和预防疫苗的化合物
公开(公告)号：WO2004006898A3
公开(公告)日：2004-02-17
申请号：PCT/DK0300486
申请日：2003-07-10
申请人： SEMA APS , CHRISTENSEN CLAUS , LUKANIDIN EUGENE , OLSEN OLE , ALBRECHTSEN MORTEN
发明人： CHRISTENSEN CLAUS , LUKANIDIN EUGENE , OLSEN OLE , ALBRECHTSEN MORTEN
IPC分类号： A61K38/00 , C07K14/47 , C07K16/18 , G01N33/574 , A61K38/17 , C12Q1/00 , G01N33/68
CPC分类号： C07K14/4703 , A61K38/00 , C07K16/18 , G01N33/57484 , G01N33/57488 , G01N2333/4704
摘要： The present invention relates to use of compounds directed to inhibiting expression and/or proteolytic processing semaphorins SEMA3E and/or sema3E and/or activation of a receptor by a proteolytic product of said semaphorins for the manufacture of a medicament for prevention, treatment, diagnosis and/or prognosis of an invasive disease. The invention features the compounds selected from the group comprising antisense compounds derived from the sequence of SEMA3E and/or sema3E, peptide compounds derived from the sequence of said semaphorins, anti-bodies against said semaphorins, and peptide compounds derived from the sequence of Plexin A receptor. Furthermore, the invention provides methods for prognosis and/diagnosis of malignancy of cancer based of estimation of the levels of expression and proteolytic processing of said semaphorins in a sample of a tissue or body fluid. The invention also concerns a method for producing an attractant polypeptide by establishing a cleavage product of SEMA3E. and/or sema3E.
摘要翻译：本发明涉及用于抑制表达和/或蛋白水解处理信号素SEMA3E和/或sema3E的化合物和/或由所述信号素的蛋白水解产物激活受体的化合物用于制备用于预防，治疗，诊断和 /或侵入性疾病的预后。本发明的特征在于选自衍生自SEMA3E和/或sema3E序列的反义化合物的组合物，衍生自所述信号素序列的肽化合物，针对所述信号素的抗体，以及衍生自Plexin A序列的肽化合物受体。此外，本发明基于对组织或体液样品中所述信号素的表达水平和蛋白水解加工的估计，提供了对癌症恶性程度的预后和/诊断方法。本发明还涉及通过建立SEMA3E的切割产物来产生引诱多肽的方法。和/或sema3E。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式